CancerDrs

Lung Cancer clinical trials in Texas

120 actively recruiting lung cancer trials at 49 sites across Texas.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 3 Recruiting NIH

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizuma…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06096844
Sites in Texas:
  • Parkland Memorial Hospital — Dallas, Texas
  • UT Southwestern Simmons Cancer Center - RedBird — Dallas, Texas
  • UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
  • UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
  • UT Southwestern Clinical Center at Richardson/Plano — Richardson, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Texas:
  • MD Anderson in The Woodlands — Conroe, Texas
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
  • Memorial Hermann Texas Medical Center — Houston, Texas
  • UT MD Anderson Cancer Center — Houston, Texas
  • MD Anderson West Houston — Houston, Texas
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Texas:
  • Local Institution - 007-554B — Abilene, Texas
  • Local Institution - 007-554G — Amarillo, Texas
  • Local Institution - 007-879-A — Arlington, Texas
  • Local Institution - 007-879-B — Arlington, Texas
  • Local Institution - 007-892-B — Austin, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…

Sponsor: Pfizer
NCT ID: NCT07222566
Sites in Texas:
  • Texas Oncology - West Texas — Abilene, Texas
  • Texas Oncology - Northeast Texas — Allen, Texas
  • Texas Oncology - West Texas — Amarillo, Texas
  • Texas Oncology - DFW — Arlington, Texas
  • Texas Oncology - DFW — Arlington, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …

Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in Texas:
  • Research Site — Fort Worth, Texas
  • Research Site — Houston, Texas
  • Research Site — Kingwood, Texas
  • Research Site — Lubbock, Texas
  • Research Site — Round Rock, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a…

Sponsor: Pfizer
NCT ID: NCT06758401
Sites in Texas:
  • The University of Texas, MD Anderson Cancer Center - Woodlands — Conroe, Texas
  • Renovatio Clinical - El Paso — El Paso, Texas
  • The University of Texas MD Anderson Cancer Center Diagnostic Imaging — Houston, Texas
  • The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services — Houston, Texas
  • The University of Texas, MD Anderson Cancer Center- Interventional Radiology — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-smal…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06077760
Sites in Texas:
  • UT Southwestern Medical Center ( Site 0061) — Dallas, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in Texas:
  • Texas Oncology - West Texas — Abilene, Texas
  • Local Institution - 0305 — Harlingen, Texas
  • University of Texas MD Anderson Cancer Center — Houston, Texas
  • The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center — Tyler, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).

Sponsor: Amgen
NCT ID: NCT07005128
Sites in Texas:
  • Texas Oncology - Dallas Fort Worth — Dallas, Texas
  • Oncology Consultants — Houston, Texas
  • US Oncology Research Investigational Products Center — Irving, Texas
  • University of Texas Health Science Center at Tyler — Tyler, Texas
  • Texas Oncology Northeast Texas — Tyler, Texas
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemot…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07063745
Sites in Texas:
  • Local Institution - 0433 — Dallas, Texas
  • Local Institution - 0374 — El Paso, Texas
  • University of Texas MD Anderson Cancer Center — Houston, Texas
  • Local Institution - 0377 — The Woodlands, Texas
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…

Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Texas:
  • Millennium Research and Clinical Development, LLC — Houston, Texas
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07100080
Sites in Texas:
  • Local Institution - 0025 — Houston, Texas
  • Local Institution - 0173 — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose t…

Sponsor: Boehringer Ingelheim
NCT ID: NCT07195695
Sites in Texas:
  • Hendrick Health — Abilene, Texas
  • The University of Texas MD Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (E…

Sponsor: Gilead Sciences
NCT ID: NCT06801834
Sites in Texas:
  • Hendrick Health System — Abilene, Texas
  • MD Anderson Cancer Center — Houston, Texas
  • Texas Oncology - San Antonio — New Braunfels, Texas
  • The University of Texas Health Science Center at Tyler — Tyler, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral on…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06345729
Sites in Texas:
  • Oncology Consultants P.A. ( Site 0113) — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging …

Sponsor: Vergent Bioscience, Inc.
NCT ID: NCT07499674
Sites in Texas:
  • University of Texas, MD Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

Lung cancer is one of the most common forms of cancer. One common type is non-small cell lung cancer (NSCLC). NSCLC happens when abnormal cells in the lungs grow too fast. This can stop the lungs from working normally. This study focuses o…

Sponsor: Takeda
NCT ID: NCT07217301
Sites in Texas:
  • The University of Texas M.D Anderson Cancer Center (MDACC) — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

This study is researching an experimental drug called REGN7508 (called "study drug") and will consist of 2 parts: Part 1 and Part 2. The study is focused on participants with or without cancer who develop blood clots in certain veins (call…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT07493304
Sites in Texas:
  • El Paso Medical Research Institute (Medresearch Inc) — El Paso, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer …

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06769126
Sites in Texas:
  • M D Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Texas:
  • New Experimental Therapeutics - NEXT Oncology — Austin, Texas
  • Texas Oncology — Bedford, Texas
  • UT Southwest Simmons Cancer Center — Dallas, Texas
  • The University of Texas MD Anderson Cancer Center — Houston, Texas
  • New Experimental Therapeutics of San Antonio - NEXT Oncology — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other…

Sponsor: Reunion Neuroscience Inc
NCT ID: NCT07002034
Sites in Texas:
  • Dell Medical School, University of Texas at Austin — Austin, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combinatio…

Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT04198766
Sites in Texas:
  • Sarah Cannon Research Institute at Mary Crowley — Dallas, Texas
  • Renovatio Clinical - El Paso — El Paso, Texas
  • NEXT Oncology — San Antonio, Texas
  • Renovatio Clinical — The Woodlands, Texas
  • The University of Texas Health Science Center at Tyler — Tyler, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1/PD-1 …

Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06095505
Sites in Texas:
  • Texas Oncology-Baylor Charles A. Sammons Cancer Center — Dallas, Texas
  • University of Texas Southwestern Medical Center — Dallas, Texas
View on ClinicalTrials.gov →

Showing 25 of 120 trials with sites in Texas. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-09-07